AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6816006
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 25 mg/kg body weight twice a day for 10 days
Trial: 31818723
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (N = 35)
Trial: 31818723
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) (N = 30)
Trial: 30385543
Drug: Daily work
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily work breaks in a hospital-integrated garden
Trial: 19614689
Drug: PGI(2) (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGI(2) (10 ng kg(‐1) min(‐1) infusion over 25 min)
Trial: 17427824
Drug: Excite bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excite bonding agent with light activation
Trial: 17427824
Drug: One‐Step bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One‐Step bonding agent with light activation
Trial: 17427824
Drug: Excite DSC
RxNorm normalized name: chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Excite DSC bonding agent with light activation
Trial: 12442921
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with cisplatin and methotrexate
Trial: 2137644
Drug: Chondroprotective agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroprotective agents
Trial: 2137644
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of OA of the knee
Trial: 382152
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg t.d.s.
Trial: 24906585
Drug: Aromatherapy massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy massage (40 min, twice per week for 4 weeks)
Trial: 24906585
Drug: Aromatherapy massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy massage (one-time treatment)
Trial: 20307214
Drug: Tacrolimus ophthalmic
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ophthalmic suspension 0.1%
Trial: 7771913
Drug: Methylphenidate hydrochloride,
RxNorm normalized name: Methylphenidate Hydrochloride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride, 1.0 mg/kg per day
Trial: 2125153
Drug: Rifampicin, streptomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3)
Trial: 2125153
Drug: The same
RxNorm normalized name: This Is The Same Medication Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same regimen as R3 followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5)
Trial: 28645997
Drug: Antibiotic-containing elastomeric
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-containing elastomeric infusion devices
Trial: 23225237
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg daily plus advice for exercise and lifestyle modification
Trial: 11101186
Drug: Dry powder
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder fluticasone propionate 200 microg once daily (QD)
Trial: 11101186
Drug: Dry powder
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder fluticasone propionate 100 microg twice daily (BID)
Trial: 9298513
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg daily, PO)
Trial: 20622656
Drug: ONS (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONS (oral nutritional supplement)
Trial: 8919902
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% at a dose of 0.5-1.0 mg/kg for spinal anesthesia
Trial: 1748115
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no antibiotic prophylaxis)
Trial: 25403163
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous cardiosphere‐derived cells (CDCs)
Trial: 23076005
Drug: Local tumescent
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local tumescent anaesthesia 0.15% TLA: ropivacaine, lidocaine, saline solution plus epinephrine 1:1,000,000
Trial: 21781649
Drug: Roflumilast (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast (500 μg, p.o.)
Trial: 19303273
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg, three times daily for four weeks)
Trial: 19303273
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin placebo, three times daily for four weeks)
Trial: 15025736
Drug: RWJ‐68023 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ‐68023 (high dose)
Trial: 15025736
Drug: RWJ‐68023 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ‐68023 (low dose)
Trial: 9745191
Drug: Isosorbide in
RxNorm normalized name: Product containing isosorbide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide in spray 1.25 mg
Trial: 9745191
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 4 g infused in one hour, then 1 g each hour for a maximum of five hours
Trial: 8521205
Drug: Intravenous chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chlorpromazine (CPZ) 0.1 mg/kg/dose, up to three doses
Trial: 8521205
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (MC) 0.1 mg/kg/dose, up to three doses
Trial: 8521205
Drug: Intravenous chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chlorpromazine (CPZ)
Trial: 8521205
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (MC)
Trial: 30726862
Drug: Glucose 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 2.5 g/day (g-group) for college students
Trial: 30726862
Drug: Sucrose 5
RxNorm normalized name: SENNA EXT 75ML/SUCROSE 50GM/75ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 5 g/day (s-group) for college students
Trial: 30726862
Drug: Fructose 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose 2.5 g/day (f-group) for adults
Trial: 30726862
Drug: Sucrose 5
RxNorm normalized name: SENNA EXT 75ML/SUCROSE 50GM/75ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose 5 g/day (s-group) for adults
Trial: 9347592
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic
Trial: 8409337
Drug: Roferon A
RxNorm normalized name: Roferon A 3million unit/ml Solution for Injection
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roferon A 3 MU administered subcutaneously 3 times weekly after hemodialysis for 6 months
Trial: 8409337
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously 3 times weekly after hemodialysis for 6 months
Trial: 30102825
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (4 μg/kg/minute for a median duration of 6.0 hours)
Trial: 24384643
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day) + ASA (325 mg/day)
Trial: 24384643
Drug: ASA (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (325 mg/day)
Trial: 12022539
Drug: Celsior solution
RxNorm normalized name: Fraxinus excelsior leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior solution for cardiac preservation
Trial: 7557846
Drug: daily IFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily IFN‐alpha
Trial: 31683483
Drug: Chlorogenic Acids
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorogenic Acids (CGA) beverage (553.6 mg/bottle) twice daily for 12 weeks
Trial: 25542620
Drug: Active care
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active care (step-up treatment for recurrence)
Trial: 25542620
Drug: Active care
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active care (no change in therapy)
Trial: 21725881
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium aescinate (5 mg)
Trial: 21725881
Drug: High-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sodium aescinate (10 mg)
Trial: 14990784
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (10 mg/day for 48 weeks)
Trial: 8317315
Drug: Indomethacin (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (topical pretreatment)
Trial: 3027836
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (200 mg once daily for five consecutive days)
Trial: 3027836
Drug: 2.5% selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% selenium sulfide shampoo (once daily application for seven days)
Trial: 25044383
Drug: Oral pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentoxifylline 400 mg/thrice-weekly
Trial: 21081728
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus sorafenib (60 mg/m² doxorubicin every 21 days + 400 mg sorafenib twice daily)
Trial: 21081728
Drug: Doxorubicin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin alone (60 mg/m² doxorubicin every 21 days + placebo)
Trial: 6314661
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (surgical and drug therapy including CCNU)
Trial: 6314661
Drug: Levomycetin as
RxNorm normalized name: Levomycetin
DrugBank: Chloramphenicol (DB00446)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levomycetin as part of combined therapy
Trial: 6314661
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cancer patients not receiving combined therapy)
Trial: 30797722
Drug: Mobile device
RxNorm normalized name: blood-glucose meter,for mobile device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile device application (app) for drug preparation
Trial: 30797722
Drug: Infusion‐rates table
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion‐rates table
Trial: 27869312
Drug: Biofeedback‐assisted pelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback‐assisted pelvic muscle therapy (BAPFMT) with the MAPLe
Trial: 25476993
Drug: Low-dose total
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose total skin electron beam therapy (12 Gy, 1 Gy per fraction over 3 weeks)
Trial: 21707601
Drug: Oral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral intervention
Trial: 21707601
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (oral+T/K)
Trial: 11606448
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg daily for 12 months)
Trial: 11606448
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically appearing tablets daily for 12 months)
Trial: 9219507
Drug: UFT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT at 12 mg/kg daily for 1 year
Trial: 8489058
Drug: Fentanyl at
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl at 1.67 ng/ml
Trial: 18958561
Drug: Radiochemotherapy (5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiochemotherapy (5-fluorouracil 200 mg/m2/day and 5040 Gy radiotherapy)
Trial: 12819941
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) administered as a constant 72-h i.v. infusion every 2 weeks at a dose of 47 microg/m2 per hour
Trial: 12819941
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) administered at 59 microg/m2 per hour
Trial: 12819941
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) administered at lower doses
Trial: 12819941
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) administered at 47 microg/m2 per hour
Trial: 12819941
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) administered at various dose levels
Trial: 9387348
Drug: Physical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical treatment (Group B)
Trial: 1432282
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg/dose, given in three doses 8 hours apart, final dose 1 hour before extubation
Trial: 30563758
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus manipulation (n=31)
Trial: 30563758
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n=30)
Trial: 25171133
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading of sodium valproate (20 mg/kg oral single-dose on the first day, then 10-15 mg/kg daily)
Trial: 25171133
Drug: Intravenous loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous loading of sodium valproate (20 mg/kg intravenous injection on the first day, then 10-15 mg/kg orally)
Trial: 25171133
Drug: Oral maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral maintenance administration of sodium valproate (15-20 mg/kg daily from the beginning)
Trial: 22351300
Drug: Conventional bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bolus dose atropine (group A)
Trial: 22351300
Drug: Rapidly incremental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly incremental doses of atropine followed by infusion (group B)
Trial: 20153039
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil
Trial: 16371681
Drug: Group workshops
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group workshops and single one-on-one tutorials with parents, teachers, and providers about the evaluation and treatment of ADHD.
Trial: 10453230
Drug: Oral co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-amoxiclav (amoxycilline and clavulanic acid)
Trial: 10453230
Drug: Intramuscular ampicilline
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ampicilline (control)
Trial: 2649120
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg twice daily increased to 10 mg twice daily after two weeks)
Trial: 16703777
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream with tape occlusion
Trial: 11845814
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily for 12 months
Trial: 320061
Drug: Diftalone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diftalone (1,000 mg during the 1st week; 750 mg the 2nd week; 500 mg from the 3rd week on)
Trial: 320061
Drug: Phenylbutazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (400 mg during the 1st week; 300 mg the 2nd week; 200 mg from the 3rd week on)
Trial: 31439579
Drug: Taselisib combined
RxNorm normalized name: Taselisib
DrugBank: Taselisib (DB12108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib combined with tamoxifen (20mg once daily)
Trial: 31439579
Drug: Taselisib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib (2 or 4 mg in an intermittent or continuous schedule)
Trial: 28927491
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution plus CPAP
Trial: 17882839
Drug: Synthetic ligands
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic ligands for Toll‐like receptors
Trial: 17882839
Drug: Polycomponent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycomponent vaccine containing antigens of opportunistic bacteria (Immunovac VP‐4)
Trial: 15220700
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of d4T
Trial: 15220700
Drug: Treatment using
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment using abacavir or zidovudine
Trial: 15220700
Drug: Serum transaminases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum transaminases normalization after d4T discontinuation
Trial: 9517940
Drug: ABCD (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCD (4 mg/kg of body weight daily) for up to 6 weeks
Trial: 7822089
Drug: Steroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (40 mg of prednisone equivalent)
Trial: 7822089
Drug: Steroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (40 mg of prednisone equivalent) + Cyclophosphamide (100 mg)
Trial: 7822089
Drug: Steroids (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (40 mg of prednisone equivalent) + Cyclosporine (5 mg/kg)
Trial: 7822089
Drug: Combination treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatments (Cyclophosphamide or Cyclosporine)
Trial: 31153362
Drug: 4 week
RxNorm normalized name: Rheumatrex Dose Pack 8, 4 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 week physiotherapy programme (6-8 sessions) of manual therapy, exercise and upper limb neural unloading tape
Trial: 31153362
Drug: Weekly phone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly phone advice (control)
Trial: 28304350
Drug: Functional bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional bread (low in starch, rich in fibers, 7 g/100 g, beta glucan/starch ratio of 7.6:100 g/g)
Trial: 16797329
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg weekly, calcium 1 g daily, calcitriol 0.5 mug daily
Trial: 19897063
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group 3, n=14)
Trial: 7790794
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy
Trial: 7790794
Drug: Amitriptyline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline therapy
Trial: 371048
Drug: Kanamycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanamycin (1 gm four times a day) and erythromycin (750 mg three times a day)
Trial: 31772611
Drug: Inulin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (15 g for 21 days)
Trial: 31772611
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 15 g for 21 days)